Firm founder Joe G. Hollingsworth is serving as a member of the Steering Committee for DePauw University’s Rector Scholarship Centennial. 2019 marks the centennial year of Edward and Lucy Rowland Rector’s historic scholarship gift in 1919,…
The ACQ5 2018 Global Awards have been announced and Hollingsworth LLP is honored to have been selected as the Complex Litigation and Pharmaceutical Products Liability Law Firm of the Year in the U.S. The awards launched…
On June 12, 2018, the Fourth Circuit unanimously affirmed a decision excluding expert causation testimony and granting summary judgment in favor of Pfizer on claims that its drug Lipitor can cause diabetes. In re: Lipitor (Atorvastatin…
To support our implementation of an array of attorney development initiatives, Hollingsworth LLP has joined the Diversity & Flexibility Alliance, a community of industry leaders at law firms, professional services firms, and corporations dedicated to flex…
In June 2017, the 3rd Circuit unanimously affirmed a decision excluding expert causation testimony and granting summary judgment in favor of Pfizer on claims that its anti-depressant drug Zoloft can cause cardiac birth defects if taken…
February 2017 — Hollingsworth LLP flexed its considerable Daubert muscle once again in serial pharma litigation in Jones v Novartis. With the benefit of extensive briefing by Firm partners Stephen A. Klein and Robert E. Johnston, and…
Firm partner, Don Fowler, has been named to the 2017 “Environmental Lawyer of the Year” list by Corporate LiveWire‘s M&A Awards. The awards recognize individuals that have consistently shown best practice and demonstrated general excellence throughout…
Global Law Experts (GLE), a premier guide to leading attorneys throughout the world, has named Hollingsworth LLP as the winner in two award categories — High Stakes Litigation Law Firm and Pharmaceutical Products Liability Law Firm…
H.(T.) v. Novartis Pharm. Corp., No. S233898, -- P.3d --, 2016 WL 3192406 (Cal. June 8, 2016)
